Share on StockTwits

BioScrip (NASDAQ:BIOS) Director Yon Jorden acquired 5,000 shares of the stock on the open market in a transaction that occurred on Wednesday, May 14th. The shares were purchased at an average cost of $7.21 per share, with a total value of $36,050.00. Following the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $108,150. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of BioScrip in a research note on Monday, April 14th. They now have a $7.50 price target on the stock. Separately, analysts at Sidoti downgraded shares of BioScrip from a “buy” rating to a “neutral” rating in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. BioScrip currently has a consensus rating of “Buy” and an average target price of $9.80.

BioScrip (NASDAQ:BIOS) traded down 0.83% during mid-day trading on Thursday, hitting $7.16. 1,044,076 shares of the company’s stock traded hands. BioScrip has a 52-week low of $5.61 and a 52-week high of $17.62. The stock has a 50-day moving average of $7.09 and a 200-day moving average of $7.20. The company’s market cap is $488.3 million.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.03) by $0.10. The company had revenue of $239.60 million for the quarter, compared to the consensus estimate of $222.65 million. On average, analysts predict that BioScrip will post $-0.09 earnings per share for the current fiscal year.

BioScrip, Inc (NASDAQ:BIOS) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.